Cargando…

Rapid Administration of High-Dose Intravenous Methylprednisolone Improves Visual Outcomes After Optic Neuritis in Patients With AQP4-IgG-Positive NMOSD

Objective: The purpose of this study was to elucidate the rapid impact of high-dose intravenous methylprednisolone pulse therapy (1,000 mg/day for 3 days) on the eventual visual prognosis in patients with serum anti-aquaporin-4 immunoglobulin G (AQP4-IgG)–positive neuromyelitis optica spectrum disor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akaishi, Tetsuya, Takeshita, Takayuki, Himori, Noriko, Takahashi, Toshiyuki, Misu, Tatsuro, Ogawa, Ryo, Kaneko, Kimihiko, Fujimori, Juichi, Abe, Michiaki, Ishii, Tadashi, Fujihara, Kazuo, Aoki, Masashi, Nakazawa, Toru, Nakashima, Ichiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505044/ https://www.ncbi.nlm.nih.gov/pubmed/33013632 http://dx.doi.org/10.3389/fneur.2020.00932

Ejemplares similares

Optic neuritis after ocular trauma in anti‐aquaporin‐4 antibody‐positive neuromyelitis optica spectrum disorder
por: Akaishi, Tetsuya, et al.
Publicado: (2021)

Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder
por: Akaishi, Tetsuya, et al.
Publicado: (2021)

CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications
por: Kaneko, Kimihiko, et al.
Publicado: (2018)

Area postrema syndrome: Frequency, criteria, and severity in AQP4-IgG–positive NMOSD
por: Shosha, Eslam, et al.
Publicado: (2018)

Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease
por: Akaishi, Tetsuya, et al.
Publicado: (2021)

Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders
por: Akaishi, Tetsuya, et al.
Publicado: (2020)

Epitope Analysis of Cerebrospinal Fluid IgG in Japanese Multiple Sclerosis Patients Using Phage Display Method
por: Fujimori, Juichi, et al.
Publicado: (2011)

Early Treatment Initiation With Oral Prednisolone for Relapse Prevention Alleviates Depression and Fatigue in Aquaporin-4–Positive Neuromyelitis optica Spectrum Disorder
por: Akaishi, Tetsuya, et al.
Publicado: (2021)

The use of OCT in good visual acuity MOGAD and AQP4-NMOSD patients; with and without optic neuritis
por: Roca-Fernández, A, et al.
Publicado: (2021)

International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab
por: Paul, Friedemann, et al.
Publicado: (2023)

AQP4‐IgG positive paraneoplastic NMOSD: A case report and review
por: Ding, Manqiu, et al.
Publicado: (2021)

AQP4-IgG NMOSD, MOGAD, and double-seronegative NMOSD: is it possible to depict the antibody subtype using magnetic resonance imaging?
por: Fragoso, Diego Cardoso, et al.
Publicado: (2023)

White blood cell count profiles in multiple sclerosis during attacks before the initiation of acute and chronic treatments
por: Akaishi, Tetsuya, et al.
Publicado: (2021)

White blood cell count profiles in anti-aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorder and anti-myelin oligodendrocyte glycoprotein antibody-associated disease
por: Akaishi, Tetsuya, et al.
Publicado: (2023)

Number of MRI T1-hypointensity corrected by T2/FLAIR lesion volume indicates clinical severity in patients with multiple sclerosis
por: Akaishi, Tetsuya, et al.
Publicado: (2020)

Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD
por: Jitprapaikulsan, Jiraporn, et al.
Publicado: (2020)

A case report on recurrent area postrema syndrome in AQP4-IgG-positive NMOSD
por: Shrestha, Ramesh, et al.
Publicado: (2022)

Different clinical phenotypes of AQP4-IgG positive NMOSD in two first degree relatives
por: Ssemmanda, Salvatore, et al.
Publicado: (2023)

Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method
por: Bollo, Luca, et al.
Publicado: (2021)

MOG antibody–positive, benign, unilateral, cerebral cortical encephalitis with epilepsy
por: Ogawa, Ryo, et al.
Publicado: (2017)

Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders
por: Palace, Jacqueline, et al.
Publicado: (2019)

Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort
por: Dauby, Solène, et al.
Publicado: (2021)

An Abnormally High Neutrophil-to-Lymphocyte Ratio Is Not an Independent Outcome Predictor in AQP4-IgG-Positive NMOSD
por: Carnero Contentti, Edgar, et al.
Publicado: (2021)

Structural and Functional Alterations in Visual Pathway After Optic Neuritis in MOG Antibody Disease: A Comparative Study With AQP4 Seropositive NMOSD
por: Gao, Chenyang, et al.
Publicado: (2021)

Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD
por: Dinoto, Alessandro, et al.
Publicado: (2022)

Microstructural visual system changes in AQP4-antibody–seropositive NMOSD
por: Oertel, Frederike C., et al.
Publicado: (2017)

The effect of smoking on MRI lesion resolution in NMOSD-AQP4 and MOGAD
por: Berhanu, David, et al.
Publicado: (2023)

Impaired response of blood neutrophils to cell-death stimulus differentiates AQP4-IgG-seropositive NMOSD from MOGAD
por: Schroeder-Castagno, Maria, et al.
Publicado: (2022)

Elevated serum levels of bone morphogenetic protein-9 are associated with better outcome in AQP4-IgG seropositive NMOSD
por: Masuda, Hiroki, et al.
Publicado: (2023)

Long‐Term Safety and Efficacy of Eculizumab in Aquaporin‐4 IgG‐Positive NMOSD
por: Wingerchuk, Dean M., et al.
Publicado: (2021)

Paraneoplastic NMOSD associated with EG junction adenocarcinoma expressing unprotected AQP4
por: Sudo, Atsushi, et al.
Publicado: (2018)

Myelitis features and outcomes in CNS demyelinating disorders: Comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD
por: Fadda, Giulia, et al.
Publicado: (2022)

Normal volumes and microstructural integrity of deep gray matter structures in AQP4+ NMOSD
por: Finke, Carsten, et al.
Publicado: (2016)

AQP4 Antibody Assay Sensitivity Comparison in the Era of the 2015 Diagnostic Criteria for NMOSD
por: Prain, Kerri, et al.
Publicado: (2019)

Effects of erythropoietin and methylprednisolone on AQP4 expression in astrocytes
por: Wang, Changchao, et al.
Publicado: (2017)

Factors influencing intravenous methylprednisolone pulse therapy in Chinese patients with isolated optic neuritis associated with AQP4 antibody-seropositive neuromyelitis optica
por: Guo, Sitong, et al.
Publicado: (2021)

Circulating AQP4-specific auto-antibodies alone can induce neuromyelitis optica spectrum disorder in the rat
por: Hillebrand, Sophie, et al.
Publicado: (2018)

Complement-dependent cytotoxicity of human autoantibodies against myelin oligodendrocyte glycoprotein
por: Kohyama, Kuniko, et al.
Publicado: (2023)

An elderly female case of AQP4 and GFAP double-positive NMOSD coexisting with ovarian teratoma
por: Yang, Jiahui, et al.
Publicado: (2023)

Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation
por: Khalilidehkordi, Elham, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6p4h96p6jpu9kpgd8jqj920jtk